ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 82

HLA-DPB1*04:01 Confers Risk for PR3-ANCA Positive ANCA-Associated Vasculitis (AAV), but Protects Against MPO-ANCA Positive AAV, in a Japanese Population

Aya Kawasaki1, Misaki Hidaka2, Narumi Hasebe2, Ken-ei Sada3, Shigeto Kobayashi4, Hidehiro Yamada5, Hiroshi Furukawa6, Kunihiro Yamagata7, Takayuki Sumida8, Nobuyuki Miyasaka9, Shigeto Tohma6, Shoichi Ozaki10, Seiichi Matsuo11, Hiroshi Hashimoto12, Hirofumi Makino3, Masayoshi Harigai13 and Naoyuki Tsuchiya1, 1Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 3Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 4Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, 5Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 6Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 7Department of Internal Medicine (Nephrology), Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 8Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 9Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 10Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 11Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 12Juntendo University School of Medicine, Tokyo, Japan, 13Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Disease susceptibility, genetics, human leukocyte antigens (HLA), myeloperoxidase (MPO) and polymorphism

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics, Genomics and Proteomics I

Session Type: Abstract Submissions (ACR)

Background/Purpose

Epidemiologic difference between European and Asian populations is observed in antineutrophil cytoplasmic antibody (ANCA) – associated vasculitis (AAV). Granulomatosis with polyangiitis (GPA) is prevalent in European populations, while microscopic polyangiitis (MPA) is common in Japanese. Genetic factors appear to contribute to the difference in epidemiology, which was supported by a recent genome-wide association study (GWAS) (Lyons et al., 2012). The GWAS indicated that GPA / proteinase 3 (PR3)-ANCA was associated with HLA-DP region, whereas MPA / myeloperoxidase (MPO) – ANCA was associated with HLA-DQ region. These results were consistent with the previous studies showing the association of GPA with HLA-DPB1*04:01 in European populations, as well as our study that reported HLA-DRB1*09:01-DQB1*03:03 haplotype was associated with MPA in Japanese (Tsuchiya et al., 2006). However, due to the rarity of AAV, contribution of HLA-DPB1 to either MPA or GPA has not been reported in a Japanese population.

In this study, by means of multicenter collaborative study in Japan, we investigated whether HLA-DPB1 is associated with susceptibility to AAV in Japanese, and whether the differences in HLA-DPB1 allele frequency can in part account for the population difference in AAV subsets.

Methods

Association of HLA-DPB1 was examined in 356 Japanese patients with AAV and 580 healthy controls. According to the European Medicines Agency algorithm, 220 patients were classified as MPA, 69 as GPA and 35 as eosinophilic granulomatosis with polyangiitis (EGPA). Among the patients, 300 were positive for MPO-ANCA and 41 were positive for PR3-ANCA. HLA-DPB1 typing was performed by the PCR-SSOP (Sequence Specific Oligonucleotide probes) method.

Results

HLA-DPB1*04:01, which was reported to be a risk allele to GPA in European populations, is decreased in MPA (dominant model, P=0.031, odds ratio [OR] 0.53), and more strikingly in MPO-ANCA positive AAV (P=0.0026, OR 0.44). DPB1*05:01 was also decreased in MPA (allele model, P=0.0063, OR 0.72). On the other hand, DPB1*04:01 was increased in PR3-ANCA positive AAV (allele model, P=0.010, OR 2.38). Interestingly, although significant association was not detected in GPA as a whole, DPB1*04:01 was significantly increased when only PR3-ANCA positive GPA was examined (P=5.7E-4, OR 3.18), but not in MPO-ANCA positive GPA.

Conclusion

This study demonstrated that DPB1*04:01 is a risk allele to PR3-ANCA positive AAV also in the Japanese population. In contrast. DPB1*04:01 was protective against MPO-ANCA positive AAV. In view of the population difference in the DPB1*04:01 allele frequency in the Japanese (6.1%) and in the European populations (42.5% in USA, The Allele Frequency Net Database), DPB1*04:01 may in part account for the epidemiological difference in the prevalence of MPO-ANCA and PR3-ANCA positive AAV, in addition to the DRB1*09:01-DQB1*03:03 haplotype.

Table 1 Association of DPB1*04:01 with AAV in a Japanese population.

n

Allele frequency

P

OR(95%CI)

Carrier frequency

P

OR(95%CI)

MPA

220

16(0.036)

0.050

0.58(0.33-1.00)

15(0.068)

0.031

0.53(0.30-0.95)

GPA

69

12(0.087)

0.24

1.46(0.77-2.76)

10(0.145)

0.56

1.23(0.60-2.52)

MPO+ GPA

39

2(0.026)

0.32

0.40(0.10-1.68)

 

2(0.051)

0.30

0.39(0.09-1.67)

PR3+ GPA

32

11(0.172)

5.7X10-4

3.18(1.65-6.15)

9(0.281)

0.0084

2.85(1.31-6.21)

MPO+ AAV

300

18(0.030)

0.0046

0.47(0.28-0.79)

17(0.057)

0.0026

0.44(0.26-0.75)

PR3+ AAV

41

11(0.134)

0.010

2.38(1.23-4.60)

9(0.220)

0.066

2.05(0.95-4.41)

Healthy control

580

71(0.061)

70(0.121)


Disclosure:

A. Kawasaki,
None;

M. Hidaka,
None;

N. Hasebe,
None;

K. E. Sada,
None;

S. Kobayashi,
None;

H. Yamada,
None;

H. Furukawa,
None;

K. Yamagata,
None;

T. Sumida,
None;

N. Miyasaka,
None;

S. Tohma,
None;

S. Ozaki,
None;

S. Matsuo,
None;

H. Hashimoto,
None;

H. Makino,
None;

M. Harigai,
None;

N. Tsuchiya,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hla-dpb10401-confers-risk-for-pr3-anca-positive-anca-associated-vasculitis-aav-but-protects-against-mpo-anca-positive-aav-in-a-japanese-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology